Moberg Pharma (OTCPK:MBGP.F) - Stock Price, News & Analysis

MBGP.F Stock Overview

A pharmaceutical company, develops and commercializes medical products primarily in Sweden. More details

MBGP.F fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 74.9% below our estimate of its fair value

Revenue is forecast to grow 105.03% per year

Risk Analysis

Makes less than USD$1m in revenue (SEK9M)

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the US market

Does not have a meaningful market cap ($896M)

Moberg Pharma AB (publ) Competitors

VYNE Therapeutics

NasdaqCM:VYNE

US$41.6m

Ikena Oncology

NasdaqGM:IKNA

US$82.0m

Landos Biopharma

NasdaqCM:LABP

US$71.7m

ALT5 Sigma

NasdaqCM:ALTS

US$28.0m

Price History & Performance

Summary of all time highs, changes and price drops for Moberg Pharma
Historical stock prices
Current Share Price	SEK 1.78
52 Week High	SEK 4.30
52 Week Low	SEK 0.91
Beta	0.78
11 Month Change	64.81%
3 Month Change	-44.35%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	-76.42%
Change since IPO	-71.57%

Recent updates

Shareholder Returns

	MBGP.F	US Pharmaceuticals	US Market
7D	29.0%	-1.4%	0.3%
1Y	n/a	10.8%	31.1%

Return vs Industry: Insufficient data to determine how MBGP.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how MBGP.F performed against the US Market.

Price Volatility

Is MBGP.F's price volatile compared to industry and market?
MBGP.F volatility
MBGP.F Average Weekly Movement	22.8%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stable Share Price: MBGP.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: MBGP.F's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2006	9	Anna Ljung	www.mobergpharma.se

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It develops MOB-015, which has completed Phase III clinical trial for the treatment of nail fungus. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013.

Moberg Pharma AB (publ) Fundamentals Summary

How do Moberg Pharma's earnings and revenue compare to its market cap?
MBGP.F fundamental statistics
Market cap	US$81.01m
Earnings (TTM)	-US$1.65m
Revenue (TTM)	US$794.15k

102.0x

P/S Ratio

-49.1x

P/E Ratio

Is MBGP.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MBGP.F income statement (TTM)
Revenue	SEK 8.78m
Cost of Revenue	SEK 2.33m
Gross Profit	SEK 6.45m
Other Expenses	SEK 24.70m
Earnings	-SEK 18.25m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 11, 2025

Earnings per share (EPS)	-0.39
Gross Margin	73.46%
Net Profit Margin	-207.75%
Debt/Equity Ratio	0%

How did MBGP.F perform over the long term?

See historical performance and comparison

Moberg Pharma OTCPK:MBGP.F Stock Report